HomeEnglishBusinessEli Lilly obesity pill orforglipron led to 12% weight loss

Eli Lilly obesity pill orforglipron led to 12% weight loss

An indication with the company’s logo sits outside the headquarters of Elli Lily in Indiana, Indiana on March 17, 2024.

Scott Olson | Getty images

Ellie lily Its highest dose on Thursday said Daily obesity pill Patients were helped to lose about 12% of their body weight or about 27 pounds, in late stage testing in 72 weeks, paved the way for its entry into the market.

The bullet weight loss was 11.2% when analyzing all patients.

The company’s shares fell more than 7% in premarket trading on Thursday. Meanwhile, rival shares Novo nordiskWhich is also working to bring obesity pill to the market, jumped more than 7% on Thursday.

Under the data, some Wall Street analysts expected Eli Lily’s oral GLP -1, which was expected to lose about 15%. Some doctors said that the results seem comparable, but the total weight loss level was seen in total Novo nordiskObesity, blockbuster weekly GLP -1 injection for Vagovi.

Some doctors also paid attention to the number of patients at the highest dosage of the bullet, who stopped treatment due to side effects or any other reason in testing.

Nevertheless, other doctors appreciated the results and pellet ability to reach new patients, such as those who are afraid of needles.

“This is a strong and promising result for an oral agent,” Dr. Dr., Medical Director of Wat Wellness Program at UT Southwestern Medical Center. The weight loss is called “an important and clinically meaningful results”, Jaime Almandoz said. ,

“Injected by the injectables have determined a higher bar, but the study confirms the ability to be transformative in obesity care for an oral GLP -1, especially for patients who hesitate to start or maintain injection therapy,” they continued.

The doctors of the Johns Hopkins community, Dr. Endocrine Hospital Director Dr. Mihle “Misha” Zillabermint said that he believes that the bullet “is the ability to be a game changer, as long as people can tolerate side effects.”

Testing results are among the most closely viewed studies of the year of the pharmaceutical industry, and follow Positive data from a phase 3 test in April Experimental pill checking in diabetic patients. They bring Eli lily pill, Orforglipron, a step potentially becomes a new, needle-free option, which is called GLP-1s without dietary restrictions in the rapidly growing market for weight loss and diabetes drugs.

Ellie Lily “is not disappointed with these results. It is right for us on thesis,” “Despite being one or two points below the road,” CEO David Ricks told about CNBC’s “” that CNBC’s “CNBC of CNBC”Squalk box“On Thursday.

“The goal was to make an oral pill that was convenient and can be made for a large scale, in fact, for a large -scale market, and for weight loss that was competitive with other single -acting GLP -1, and that is what we have achieved,” Ricks said. He said that the percentage of weight loss pellet is “in the range” that most people who are overweight or want to improve their metabolic health.

Elie Lily CEO David Ricks Q2 earnings, obesity pill late phase test results

Ricks said Eli Lily hopes to submit data to regulators by the end of the year, which is expected to launch a bullet worldwide “this time next year.”

This launch can fundamentally move space, which can help more patients reach treatment and reduce the lack of current injections supply. The more convenient and easy-to-build pill can also help Ellie Lily to strengthen its dominance as its main rival Novo Nordisk in the growing segment, which is a race to bring weight loss pills to the market.

In an interview, Kane Caster, president of Lily Cardiometabolic Health, said that there are about 8 million patients on injected obesity and diabetes drugs, but about 170 million who can benefit from drugs.

He said, “To meet that demand, we need other options, including oral small molecules such as Orglipron, which use various means of production and also do not need to distribute patients as the sophisticated of the supply chain to distribute patients,” he said.

Dr. Professor of Medicine and Program Director of Obesity Medicine Fellowship at Florida University. Amy Sareer said that he hoped that the pill would be less expensive than the current injections, which are expensive due to large -scale devices that are due to the upcoming devices.

Many insurers still do not cover GLP-1s for obesity. There is a list of approximately $ 1,000 before insurance in the list of vegovi and other drugs.

Detailed testing results

According to the results of the test, the highest dose of Ellie Lily tablet helped more than 59% of patients to lose weight at least 10% of their body weight and more than 39% patients to lose 15% weight.

Almandoz stated that the ratio of people achieving “greater magnitude” of weight loss was very impressive for an oral agent, “saying that many people often ignore the ratio of people receiving these high weight loss categories” and usually focus on average weight loss.

Orforglipron also helped reduce heart risk factors.

But the data came under the estimates of some analysts on how well some patients tolerated the pill in the test.

About 10.3% of the patients who took the highest dose of the pellet – 36 mg – stopped treatment due to side effects, while about 2.6% of those taking a placebo. Those side effects were primarily gastrointestinal, such as nausea and vomiting, and mild to moderate in severity. The estimated 24% who experienced the highest dose experience vomiting, while 33.7% and 23.1% had nausea and diarrhea respectively.

Further to the data, Ivan Segaraman, an analyst of BMO Capital Markets, said that he expected less than 10% of patients at the highest dose of the tablet to stop treatment due to side effects and low rates of vomiting, nausea and diarrhea.

Brigham and the co-director of Wait Management and Wellness at Women’s Hospital, Dr. Caroline Aphovian said that more patients stopped taking the bullet due to side effects due to side effects than the current GLP -1S on the market. Weekly obesity injection of Vegovi and Ellie Lily has dissection rates due to side effects in late stages tests on ZEPBound About 7% Or less.

He said that at the highest dose of the bullet, about a quarter of the patients stopped treatment for any reason, ensuring that the enthusiasm for Orforglipron should be angry “because we get all this enthusiasm, and then the bullet comes out, and then no one can take it.”

It is not clear that, in addition to side effects, those patients shut down the bullet. About 30% of people on a placebo stopped treatment for any reason.

Elli Lily’s Ricks said that the company is not worried about those dropout rates in the study.

He said, “What we really want to see is that the medicine dropout is lower than the placebo, and that is what we have seen here,” he said, referring to the dissection rates for any reason.

Ricks said Eli Lily was looking for less than 12% dropout rate due to side effects, given that the industry has seen 8% to 12% rate with GLP -1 drugs.

“We are right in the middle,” he said. “Continuity rate in this category, in all chronic drug categories, are not right. But the dropout from the drug pays attention to it, and here again, we are correct with the profile.”

Sarasar of the University of Florida said that she does not believe that the dissection rate or side effects would be a decisive factor for doctors when determining the pill.

They believe that an oral option can actually make more physicians more comfortable in determining GLP-1. Some physicians are currently hesitant to write injections because they “do not know how to tell patients how to use them,” said Sarasar.

Almandose said that the decision -making decisions are the patient’s specific requirements and preferences to depend on access and ability. An injected GLP-1 can be a preferred option for patients who have a large level of weight loss or who have significant cardiometabolic complications, or health issues that arise from cardiovascular diseases and metabolic disorders.

But an oral GLP-1 can be the best fit for those who “prefer simplicity or convenience or face these logistic challenges with injections,” he said.

Detailed results from the test will be presented at an European medical meeting in September and a colleague will be published in the reviewed magazine. At the end of this year, more steps on the pill will be shared by three test results, including a study on adults, who have obesity or weighing over and type 2 diabetes.

Vagovi, Elli Lily Pills, Orfluipron and Novo Nordisk’s diabetes pill ribbels all work, which works by targeting an intestine hormone called GLP -1 to promote weight loss and regulate blood sugar. But unlike those other drugs, Ellie lily pill is not a peptide drug. This means that it is more easily absorbed in the body and does not require dietary restrictions like Rybellas.

Eli Lily is currently almost three years ahead of developing pills by other drug manufacturers, including Fizer, Astrazheneka, Rush, Structure medical science And Viking theraputicsGugneheim analyst Seemus Fernandez first CNBC.

Some analysts hope that the market for GLP-1s will be more than $ 150 billion annually in the early 2030s. Oral GLP-1s may increase the price of $ 50 billion of that total, Fernandez said.

– CNBC’s Angelica Pables contributed to this report.

Do not miss these insights from CNBC Pro

Source link

RELATED ARTICLES
- Advertisment -

Most Popular